文献速递肝病消化道肿瘤与早癌

恩替卡韦与替诺福韦预防慢性乙型肝炎患者肝细胞癌的比较有效性:系统综述与Meta分析

Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
PubMed 文献 · Hepatology · 2020-11-06

该系统综述与Meta分析纳入14项研究(263,947人年),比较恩替卡韦(ETV)与替诺福韦(TDF)对慢性乙型肝炎(CHB)患者肝细胞癌(HCC)风险的影响。未调整分析显示两组HCC风险无统计学差异(IRR 1.28,95%CI 0.99-1.66);采用调整后数据时,ETV组HCC风险较TDF组高27%(95%CI 1.01-1.60,P=0.04)。结论提示TDF可能与更低的HCC风险相关。

要点

  • 未调整分析中ETV与TDF的HCC风险无显著差异(IRR 1.28,95%CI 0.99-1.66)。
  • 调整后分析显示ETV组HCC风险较TDF组高27%(95%CI 1.01-1.60,P=0.04)。
  • 肝硬化亚组调整后HR为0.90(95%CI 0.66-1.23),提示两组无差异。

核心结论

  • 与恩替卡韦(ETV)相比,替诺福韦(TDF)可能与更低的肝细胞癌(HCC)风险相关。

主要发现

  • 未调整Meta分析(14项研究)显示ETV与TDF的HCC风险无统计学差异(IRR 1.28,95%CI 0.99-1.66)。
  • 采用调整后数据(多因素或倾向匹配,7项研究)显示ETV组HCC风险较TDF组高27%(95%CI 1.01-1.60,P=0.04)。
  • 肝硬化患者调整后数据分析(单独报告)显示调整后HR为0.90(95%CI 0.66-1.23),提示ETV与TDF组无差异。
  • 总体证据置信度极低(观察性研究,异质性高)。

临床怎么用

  • 在CHB患者选择核苷(酸)类似物预防HCC时,可考虑TDF可能较ETV具有更低的HCC风险,但需结合调整后数据及肝硬化亚组结果综合判断。

局限性

  • 总体证据置信度极低,源于观察性研究设计及高异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC). While both tenofovir disoproxil (TDF) and entecavir (ETV) have been shown to reduce the risk of HCC, their comparative effectiveness is unclear. We estimated the comparative effectiveness of these two agents in reducing the risk of HCC in patients with CHB, through a systematic review and meta-analysis. APPROACH AND RESULTS: We searched multiple electronic databases from January 1, 1998, to October 31, 2019, for randomized controlled trials and observational comparative effectiveness studies in adults with CHB treated with ETV compared to TDF, reporting the incidence of HCC (minimum follow-up 12 months). Primary outcome was incidence of HCC, calculated as incidence rate ratio (IRR) with 95% confidence interval (CI, unadjusted analysis) and hazard ratio (HR) with 95% CI (adjusted analysis, where reported). Of 1,971 records identified, 14 studies (263,947 person-years) were included for quantitative analysis. On unadjusted meta-analysis of 14 studies, the risk of HCC was not statistically different between ETV and TDF (IRR, 1.28; 95% CI, 0.99-1.66). When using available adjusted data (multivariate or propensity-matched data), the risk of HCC among patients treated with ETV was 27% higher when compared to TDF (seven studies; 95% CI, 1.01-1.60, P = 0.04). Additional analysis of adjusted data when separately reported among patients with cirrhosis demonstrated an adjusted HR of 0.90 (95% CI, 0.66-1.23), suggesting no difference between ETV-treated and TDF-treated groups. The overall confidence in estimates was very low (observational studies, high heterogeneity). CONCLUSIONS: TDF may be associated with lower risk of HCC when compared to ETV.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Dave S, Park S, Murad MH, et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Hepatology. 2020. PMID: 32277491. doi:10.1002/hep.31267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。